Last Update Time:
13-Mar-2025 16:00:00
ISIN:
INE837H01020
Sector:
Healthcare
Symbol:
ADVENZYMES
Advanced Enzyme Technologies Limited
₹269.00
₹1.40
(0.52%)
▲
Prev. Close
₹267.60
Open
₹268.05
Close
₹267.00
Range
₹255.55 - ₹282.45
High
₹278.40
Low
₹265.35
Ind. Close
₹0.00
VWAP
₹270.28
The current stock price of Advanced Enzyme Technologies Limited is ₹269.00, with a target price range between ₹255.55 and ₹282.45. The stock has experienced a price change of ₹1.40 (0.52%), reflecting recent market volatility.
Today's opening price was ₹268.05, while the previous close stood at ₹267.60.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Advanced Enzyme Technologies Limited Price Chart
Advanced Enzyme Technologies Limited Pre Open Market Overview: 13-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 268.05
- Previous Close Price: 267.6
- Change: 0.45%
- Total Traded Volume: 654
- Total Buy Quantity: 39,974
- Total Sell Quantity: 3,108
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 266.00 | 122.00 | 0.00 |
| 266.40 | 118.00 | 0.00 |
| 267.80 | 23.00 | 0.00 |
| 268.00 | 100.00 | 0.00 |
| 268.05 | 0.00 | 0.00 |
| 268.10 | 388.00 | 0.00 |
| 270.55 | 0.00 | 1.00 |
| 271.55 | 0.00 | 16.00 |
| 273.00 | 0.00 | 418.00 |
| 273.20 | 0.00 | 25.00 |
| 273.50 | 0.00 | 1.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 39974
Total Sell Quantity: 3108
Shareholding Patterns of Advanced Enzyme Technologies Limited
Key Trade Statistics of Advanced Enzyme Technologies Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 2.77 |
| Traded Value (₹ Cr.) | 7.49 |
| Total Market Cap (₹ Cr.) | 3,009.59 |
| Free Float Market Cap (₹ Cr.) | 1,282.17 |
| Impact cost | 0.1 |
| Quantity Traded | 277,055.00 |
| Deliverable Quantity | 141,637.00 |
| % of Quantity to Traded | 51.12 |
| Security VaR | 15.72 |
| Index VaR | N/A |
| VaR Margin | 15.72 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 19.22 |
| Face Value | 2 |
Key Price Statistics of Advanced Enzyme Technologies Limited
The 52-week high for Advanced Enzyme Technologies Limited was ₹571.00, recorded on 16-Sep-2024. On the other hand, the 52-week low stands at ₹257.90, with the lowest value recorded on 03-Mar-2025.
The upper band for trading is ₹321.10, and the lower band is ₹214.10. The price band is 20%.
The stock's daily volatility stands at 2.43, while the annualized volatility is 46.43. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (16-Sep-2024) | 571.00 |
| 52 Week Low (03-Mar-2025) | 257.90 |
| Upper Band | 321.10 |
| Lower Band | 214.10 |
| Price Band (%) | 20 |
| Daily Volatility | 2.43 |
| Annualised Volatility | 46.43 |
| Tick Size | 0.05 |
Key Securities Statistics of Advanced Enzyme Technologies Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 01-Aug-2016 |
| Adjusted P/E | 20.29 |
| Symbol P/E | 21.79 |
| Index | NIFTY TOTAL MARKET |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Biotechnology |
Security Status of Advanced Enzyme Technologies Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Advanced Enzyme Technologies Limited
| Subject | Date |
|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 13-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 12-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 10-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 27-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 27-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 27-Feb-2025 |
| Credit Rating | 17-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 17-Feb-2025 |
Corporate Actions of Advanced Enzyme Technologies Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 2 | Dividend - Re 1.1 Per Share | 18-Jul-2024 |
| 2 | Interim Dividend - Rs 4 Per Share | 17-May-2024 |
| 2 | Dividend - Re 1 Per Share | 04-Aug-2023 |
| 2 | Interim Dividend - Rs 4 Per Share | 19-May-2023 |
| 2 | Dividend - Re 1 Per Share | 11-Aug-2022 |
| 2 | Dividend - Rs 0.90 Per Share | 31-Aug-2021 |
| 2 | Annual General Meeting/Dividend - Rs 0.60 Per Share | 09-Jul-2020 |
| 2 | Annual General Meeting/Dividend - Rs 0.60 Per Share | 01-Aug-2019 |
| 2 | Annual General Meeting/Dividend Re 0.50 Per Share | 06-Sep-2018 |
| 2 | Annual General Meeting/Dividend - Re 0.40 Per Share(Book Closure Dates Revised) | 04-Sep-2017 |
| 2 | Face Value Split From Rs 10/- Per Share To Rs 2/- Per Share | 25-May-2017 |
| 2 | Annual General Meeting | 08-Sep-2016 |
Board Meetings of Advanced Enzyme Technologies Limited
Financial Results of Advanced Enzyme Technologies Limited
Company Directory of Advanced Enzyme Technologies Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.advancedenzymes.com | Registered Office | Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, |
THANE (WEST) |
| www.advancedenzymes.com | Transfer Agent | Link Intime India Pvt. Ltd C 13, Pannalal Silk Mills Compound, LBS Marg, Bhandup (West), |
MUMBAI |
Insider Trading of Advanced Enzyme Technologies Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Kishor Laxminarayan Rathi | 0 | Buy |
| 7(2) | Vasant Rathi | 0 | Sell |
| 7(2) | Subhash Chakor | 1260885 | Sell |
| 7(2) | Madhusudan Kabra | 50896120 | Sell |
| 7(2) | Chandrakumar Laxminarayan Rathi | 6361070 | Sell |
| 7(2) | Chandrakumar Laxminarayan Rathi | 4986500 | Sell |
| 7(2) | Chandrakumar Laxminarayan Rath | 6943508 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 41089188 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 45036200 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 43953963 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 27880160 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 19979819 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 2360918 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 22084185 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 3239284 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 12568802 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 17753911 | Sell |
| 7(2) | Pramod Kasat | 1875150 | Buy |
| 7(2) | Advanced Vital Enzymes Private Limited | 38903717 | Sell |
| 7(2) | Advanced Vital Enzymes Private Limited | 16316250 | Sell |
Annual Reports of Advanced Enzyme Technologies Limited
Investor Complaints of Advanced Enzyme Technologies Limited
Event Calendar of Advanced Enzyme Technologies Limited
| Purpose | Details |
|---|---|
| Results/Others | Inter alia, to consider and transact the following matters: a) Acceptance of resignation of Mr. K. V. Ramakrishna from Directorship of the Company, b) Other incidental and ancillary matters. |
| Results/Others | inter alia, to consider and approve Standalone and Consolidated Financial Results of the Company for the Second Quarter ended on September 30, 2016 and to transact other incidental and ancillary matters. |
| Others | Inter alia, to consider and approve investment proposals of the company and incorporation of overseas subsidiaries. |
| Results/Dividend | Inter alia, to consider the following: 1. Approval of Audited Financial Results (Standalone & Consolidated) of the Company for the fourth quarter and financial year ended March 31, 2017; 2. Recommendation of the Dividend, if any, for the financial year ended March 31, 2017. |
| Others | inter alia , to consider and approve incorporation of overseas subsidiary in Netherlands and Investment thereof. |
| Others | Inter alia, to consider and approve raising of funds of the Company, by way of Qualified Institutional Placement route. |
| Board meeting Rescheduled | ADVENZYMES : 09-Aug-2017 : The Company had informed the Exchange regarding a Board meeting to be held on August 05, 2017 Inter alia, to consider and approve raising of funds of the Company, by way of Qualified Institutional Placement route. The Company has now informed the Exchange that the aforesaid Board Meeting has been Re-scheduled to August 09, 2017. |
| Results | inter alia, to consider and approve Unaudited Financial Results ( Standalone and Consolidated) of the Company for the first quarter ended June 30, 2017. |
| Results | inter alia, to consider and approve Unaudited Financial Results Standalone and Consolidated of the Company for the Second Quarter ended on September 30, 2017. |
| Results | Inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) of the Company for the third quarter ended December 31, 2017. |
| Other business matters | To consider other business matters |
| Financial Results/Dividend | Inter alia, to consider the following: 1) Approval of Audited Financial results ( Standalone & Consolidated) of the Company for the financial year ended March 31, 2018 along with results of the fourth quarter: 2) Recommendation of the Dividend, if any, for the financial year ended March 31, 2018. |
| Financial Results/Dividend | To consider the following: 1. Approval of Audited Financial Results (Standalone & Consolidated) of the Company for the financial year ended March 31, 2018 along with results of the fourth quarter.2.Recommendation of the Dividend, if any, for the financial year ended March 31, 2018. |
| Financial Results | To consider and approve the unaudited financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | Advanced Enzyme Technologies Ltd has informed NSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2022, inter alia, to consider and approve un-audited financial results (Standalone & Consolidated) of the Company for the quarter and nine months ended December 31, 2021 |
| Financial results | Advanced Enzyme Technologies Ltd has informed NSE that the meeting of the Board of Directors of the Company is scheduled on 06-08-2022, inter alia, to consider and approve un-audited financial results (Standalone and Consolidated) of the Company for the quarter ended June 30 2022 |
| Financial results | Advanced Enzyme Technologies Limited has informed the Exchange about Board Meeting to be held on 11-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | Advanced Enzyme Technologies Ltdhas informed NSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 ,inter alia, to consider and approve Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2023. |
| Financial Results/Dividend | This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Saturday, May 11, 2024, inter alia, to consider the following:To consider & approve annual Financial Statements (Standalone & Consolidated) of the Company for the financial year ended March 31, 2024 along with results of the fourth quarter;To consider & recommend Final dividend, if any, for the financial year ended March 31, 2024, and/or to consider & declare Interim Dividend, if any for the financial year ended March 31, 2025.The Record date for determining the shareholders for the payment of the aforesaid Interim Dividend for FY2024-25, if any declared by the Board of Directors of the Company shall be Saturday, May 18, 2024.Closure of Trading Window:Further to our letter dated March 29, 2024 intimating closure of Trading Window, we wish to inform you that the Trading Window for dealing in the Securities of the Company will continue to remain closed up to May 13, 2024. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Advanced Enzyme Technologies Limited
Voting Results of Advanced Enzyme Technologies Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 25-JUL-2024 | AGM | To receive, consider and adopt the Audited Financial Statements (Standalone) of the Company for the financial year ended March 31, 2024 together with the Auditors￢ﾀﾙ report thereon and the report of the Board of Directors of the Company; and the Audited Financial Statements (Consolidated) of the Company for the financial year ended March 31, 2024 together with the Auditors￢ﾀﾙ report thereon. |
| 25-JUL-2024 | AGM | Ratification of remuneration of M/s. Shilpa & Co. (Firm Registration Number:n100558), the Cost Auditors of the Company for the financial year ending March 31, 2025 |
| 25-JUL-2024 | AGM | Related Party Transactions with JC Biotech Private Limited, Subsidiary |
| 25-JUL-2024 | AGM | To appoint a Director in place of Mr. Vasant Rathi (DIN: 01233447), who retires bynrotation and being eligible, offers himself for re-appointment as a Director |
| 25-JUL-2024 | AGM | To declare final Dividend (Rs. 1.10/- per Equity Share) on the Equity Shares of Rs. 2/-neach, for the financial year ended March 31, 2024 |
| 12-AUG-2023 | AGM | To receive, consider and adopt the Audited Financial Statements (Standalone) of the Company for the financial year ended March 31, 2023 together with the Auditors￢ﾀﾙ report thereon and the report of the Board of Directors of the Company; and the Audited Financial Statements (Consolidated) of the Company for the financial year ended March 31, 2023 together with the Auditors￢ﾀﾙ report thereon. |
| 12-AUG-2023 | AGM | Approval for payment of Commission to the Non- Executive Directors for a term of five financial years commencing from April 01, 2024 |
| 12-AUG-2023 | AGM | Re-Appointment of Ms. Rajshree Patel (DIN: 08761022) as an Independent Director of the Company |
| 12-AUG-2023 | AGM | Re-Appointment of Mr. Vinodkumar Hiralal Jajoo (DIN: 08224980) as an Independent Director of the Company |
| 12-AUG-2023 | AGM | Appointment of Ms. Vandana R. Tilak (DIN: 10048021) as an Independent Director of the Company |
| 12-AUG-2023 | AGM | Related Party Transactions with JC Biotech Private Limited, Subsidiary |
| 12-AUG-2023 | AGM | To appoint a Director in place of Dr. Sunny Sharma (DIN: 02267273), who retires by rotation and being eligible, offers himself for re-appointment as a Director. |
| 12-AUG-2023 | AGM | To declare final Dividend (Rs. 1/- per Equity Share) on the Equity Shares of Rs. 2/- each, for the financial year ended March 31, 2023 |
| 19-AUG-2022 | AGM | To receive, consider and adopt the Audited Financial Statements (Standalone) of the Company for the financial year ended March 31, 2022 together with the Auditors￢ﾀﾙ report thereon and the report of the Board of Directors of the Company; and the Audited Financial Statements (Consolidated) of the Company for the financial year ended March 31, 2022 together with the Auditors￢ﾀﾙ report thereon |
| 19-AUG-2022 | AGM | Reclassification of the status from ￢ﾀﾜPromoter Group￢ﾀﾝ category to ￢ﾀﾜPublic￢ﾀﾝ category |
| 19-AUG-2022 | AGM | Appointment of Mr. Nitin Jagannath Deshmukh (DIN: 00060743) as an Independent Director of the Company |
| 19-AUG-2022 | AGM | Related Party Transactions with JC Biotech Private Limited, Subsidiary |
| 19-AUG-2022 | AGM | Continuation of Directorship of Mr. Vasant Rathi, Non-Executive Director (DIN: 01233447) in terms of Regulation 17(1A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
| 19-AUG-2022 | AGM | To appoint a Director in place of Ms. Rasika Rathi (DIN: 08300682), who retires by rotation and being eligible, offers herself for re-appointment as a Director |
| 19-AUG-2022 | AGM | To declare final Dividend (Re. 1/- per Equity Share) on the Equity Shares of Rs. 2/- each, for the financial year ended March 31, 2022 |
FAQs on Advanced Enzyme Technologies Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.